Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TGTX - TG THERAPEUTICS, INC.

IEX Last Trade
32.55
0.170   0.522%

Share volume: 23,601
Last Updated: Fri 27 Dec 2024 08:30:10 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$32.38
0.17
0.53%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 19%
Dept financing 15%
Liquidity 69%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.84%
1 Month
-4.29%
3 Months
40.58%
6 Months
86.63%
1 Year
96.48%
2 Year
328.39%
Key data
Stock price
$32.55
P/E Ratio 
37.85
DAY RANGE
$32.06 - $33.43
EPS 
$0.62
52 WEEK RANGE
$13.28 - $36.84
52 WEEK CHANGE
$96.14
MARKET CAP 
3.637 B
YIELD 
N/A
SHARES OUTSTANDING 
154.823 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
1.67
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,882,370
AVERAGE 30 VOLUME 
$1,957,376
Company detail
CEO: Michael S. Weiss
Region: US
Website: tgtherapeutics.com
Employees: 290
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.

Recent news